An update expert opinion on management and research strategies in Parkinson's disease psychosis

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 13, 2011, Pages 2009-2024

  Goldman, Jennifer G ^a   Vaughan, Christina L ^a   Goetz, Christopher G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; Cholinesterase inhibitors; Delusions; Dopamine; Hallucinations; Neuroleptic; Parkinson's disease; Psychosis

Indexed keywords

ARIPIPRAZOLE; CHOLINESTERASE INHIBITOR; CLOZAPINE; MELPERONE; OLANZAPINE; PIMAVANSERIN; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; CHOLINERGIC SYSTEM; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG WITHDRAWAL; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; HYPOTENSION; LOW DRUG DOSE; MEDLINE; NEUROIMAGING; NEUTROPENIA; NONHUMAN; PARKINSON DISEASE; PHENOMENOLOGY; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; STUDY DESIGN;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051482090     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.587122     Document Type: Review

References (100)

1. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010;25:2493-500
2. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010;289:12-17 A nice review of the epidemiology of PD psychosis.
3. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-61 (Pubitemid 36737069)
4. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-71 Early study suggesting the association of hallucinations and nursing home placement.
5. Stella F, Banzato CE, Quagliato EM, et al. Psychopathological features in patients with Parkinson's disease and related caregivers' burden. Int J Geriatr Psychiatry 2009;24:1158-65
6. McKinlay A, Grace RC, Dalrymple-Alford JC, et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat Disord 2008;14:37-42
7. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain 2000;123:733-45 Provides well-characterized, clinical descriptions of the PD psychosis spectrum. (Pubitemid 30162723)
8. Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:434-40 (Pubitemid 27423547)
9. Sanchez-Ramos JR ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;53:1265-8 (Pubitemid 26425072)
10. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 2005;252:753-64 (Pubitemid 40984849)
11. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model. Mov Disord 2005;20:130-40 (Pubitemid 40361115)
12. Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's disease. Parkinsonism Relat Disord 2004;10:253-4 (Pubitemid 38534620)
13. Fenelon G, Thobois S, Bonnet AM, et al. Tactile hallucinations in Parkinson's disease. J Neurol 2002;249:1699-703 (Pubitemid 36269262)
14. Black DW, Boffeli TJ. Simple schizophrenia: Past, present and future. Am J Psychiatry 1989;146:1267-73 (Pubitemid 19258472)
15. Aarsland D, Marsh L, Schrag A. Neuropsychiatric Symptoms in Parkinson's Disease. Movement Disorders 2009;24:2175-86
16. Stewart JT. Fregoli syndrome associated with levodopa treatment. Mov Disord 2008;23:308-9 (Pubitemid 351311572)
17. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. Mov Disord 2007;22:1061-8 Report of NINDS-NIMH work group on proposed diagnostic criteria for PD psychosis. (Pubitemid 47067214)
18. Fenelon G, Soulas T, Zenasni F, et al. The changing face of Parkinson's disease-associated psychosis: A cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord 2010;25:755-9
19. Moskovitz C, Moses H 3rd, Klawans HL. Levodopa-induced psychosis: A kindling phenomenon. Am J Psychiatry 1978;135:669-75 (Pubitemid 8344603)
20. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982;139:494-7 (Pubitemid 12141048)
21. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: High-dose challenge does not precipitate hallucinations. Neurology 1998;50:515-17 (Pubitemid 28119803)
22. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: A retrospective autopsy study. Lancet Neurol 2005;4:605-10 (Pubitemid 41317294)
23. Koller WC, Weiner WJ, Perlik S, et al. Complications of chronic levodopa therapy: Long-term efficacy of drug holiday. Neurology 1981;31:473-6 (Pubitemid 11151091)
24. de Smet Y, Ruberg M, Serdaru M, et al. Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:1161-4 (Pubitemid 13166269)
25. Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-76
26. Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Mov Disord 2007;22(Suppl 17):S351-7 (Pubitemid 350134188)
27. Perry EK, Perry RH. Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995;28:240-58
28. Zweig RM, Jankel WR, Hedreen JC, et al. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 1989;26:41-6 (Pubitemid 19190041)
29. Bhasin M, Rowan E, Edwards K, et al. Cholinesterase inhibitors in dementia with Lewy bodies: A comparative analysis. Int J Geriatr Psychiatry 2007;22:890-5 (Pubitemid 47455272)
30. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-907 (Pubitemid 44848936)
31. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18 (Pubitemid 39603164)
32. Birkmayer W, Danielczyk W, Neumayer E, et al. Nucleus ruber and L-dopa psychosis: Biochemical post-mortem findings. J Neural Transm 1974;35:93-116
33. Birkmayer W, Birkmayer JD. Dopamine action and disorders of neurotransmitter balance. Gerontology 1987;33:168-71 (Pubitemid 17124823)
34. Huot P, Johnston TH, Darr T, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010;25:1399-408
35. Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67:416-21
36. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep and Parkinson's disease: A medical hypothesis. Neurology 2000;55:281-8 Discussion of link between hallucinations and sleep disturbances. (Pubitemid 30604632)
37. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993;34:710-14 (Pubitemid 23333244)
38. Jouvet MDF. Locus coeruleus et sommeil paradoxal. CR Soc Biol 1965;159:895-99
39. Rabey JM, Vardi J, Askenazi JJ, et al. L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients. Gerontology 1977;23:438-44 (Pubitemid 8135100)
40. Voon V, Fox S, Butler TR, et al. Antidepressants and psychosis in Parkinson disease: A case series. Int J Geriatr Psychiatry 2007;22:601-4 (Pubitemid 46951761)
41. Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:311-13 (Pubitemid 44959243)
42. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease: An Evidence-Based review. Mov Disord 2002;17(Suppl 4):S1-166 Evidence-based review of treatments for PD psychosis, initial report from the MDS.
43. Seppi K, Weintraub D, Coelho M, et al. Movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of parkinson's disease. Mov Disord 2011, in press Evidence-based review of treatments for PD psychosis, follow-up report from the MDS.
44. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: Evaluation and treatment of depression, psychosis and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002 Evidence-Based review of treatments for PD psychosis and other neuropsychiatric issues from the AAN. (Pubitemid 44044781)
45. Group TPS. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-63 US-based, double-blind, placebo controlled study of clozapine in PD psychosis; along with the French study also published in 1999, represents the first, well-designed randomized, controlled studies of clozapine vs. placebo.
46. Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: A preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002;23(Suppl 2):S89-90 (Pubitemid 35355791)
47. Group TFCPS. Clozapine in drug - induced psychosis in Parkinson's disease. The Lancet 1999;353:2041-42 French-based, double-blind, placebo controlled study of clozapine in PD psychosis.
48. Factor SA, Friedman JH, Lannon MC, et al. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16:135-9 (Pubitemid 36041128)
49. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-95 (Pubitemid 38526677)
50. Morgante L EA, Spina E, Zappia M, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-6 (Pubitemid 39121725)
51. Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: Quetiapine Versus clozapine for Parkinson's disease Psychosis. Clin Neuropharmacol 2006;26:331-7 (Pubitemid 44729944)
52. Trifiro G, Verhamme KM, Ziere G, et al. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 2007;16:538-44 (Pubitemid 46824275)
53. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-63 (Pubitemid 41419510)
54. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-18
55. Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009;5:327-32
56. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: Results from a double-blind clinicalpolysomnography study. Int J Neurosci 2009;119:2196-205 Small, pilot study focused on quetiapine's effect on sleep but the only positive study comparing quetiapine vs. placebo.
57. Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and Parkinsonism. Neurology 2007;68:1356-63 (Pubitemid 46659086)
58. Goetz CG, Blasucci L, Leurgans S, Pappert EJ. Olanzapine and clozapine Comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-94
59. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-45 (Pubitemid 35266735)
60. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-5 (Pubitemid 36041010)
61. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010;35:881-92
62. Friedman JH, Ravina B, Mills R, et al. A multicenter, placebo controlled, double blind trial to examine the safety and efficacy of pimavanserin in the treatment of psychosis in Parkinson's disease. Neurology 2010;74(S2):A299
63. Teegarden BR, Al Shamma H, Xiong Y. 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem 2008;8:969-76
64. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994;343:1370-1 (Pubitemid 24162601)
65. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial. Mov Disord 2000;15:1230-7
66. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-9 (Pubitemid 26001766)
67. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000;12:364-9 (Pubitemid 30665218)
68. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: Preliminary experience. Clin Neuropharmacol 2004;27:4-5 (Pubitemid 38280379)
69. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21:2078-81 (Pubitemid 46140415)
70. Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006;21:1538-9 (Pubitemid 44613323)
71. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005;28:111-14 (Pubitemid 40923408)
72. Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007;109:188-91 (Pubitemid 46073393)
73. Meltzer HY, Koenig JI, Nash JF, et al. Melperone and clozapine: Neuroendocrine effects of atypical neuroleptic drugs. Acta Psychiatr Scand Suppl 1989;352:24-9 (Pubitemid 19247021)
74. Barbato L, Monge A, Stocchi F, et al. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct Neurol 1996;11:201-7 (Pubitemid 26363162)
75. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-12 (Pubitemid 34557010)
76. Ramirez-Ruiz B, Marti MJ, Tolosa E, et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol 2007;14:750-6 (Pubitemid 47012171)
77. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol 2008;255:1324-31
78. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, et al. Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry 2010;81:650-7
79. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: An fMRI study. Neurology 2004;63:1409-16 (Pubitemid 39426273)
80. Ramirez-Ruiz B, Marti MJ, Tolosa E, et al. Brain response to complex visual stimuli in Parkinson's patients with hallucinations: A functional magnetic resonance imaging study. Mov Disord 2008;23:2335-43
81. Meppelink AM, de Jong BM, Renken R, et al. Impaired visual processing preceding image recognition inV Parkinson's disease patients with visual hallucinations. Brain 2009;132:2980-93
82. Okada K, Suyama N, Oguro H, et al. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J Neurol 1999;246:365-8 (Pubitemid 29261425)
83. Matsui H, Nishinaka K, Oda M, et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord 2006;21:2140-4 (Pubitemid 46140426)
84. Boecker H, Ceballos-Baumann AO, Volk D, et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007;64:984-8 (Pubitemid 47047998)
85. Nagano-Saito A, Washimi Y, Arahata Y, et al. Visual hallucination in Parkinson's disease with FDG PET. Mov Disord 2004;19:801-6 (Pubitemid 39139591)
86. Arbouw ME, van Vugt JP, Egberts TC, et al. Pharmacogenetics of antiparkinsonian drug treatment: A systematic review. Pharmacogenomics 2007;8:159-76
87. Skipper L, Liu JJ, Tan EK. Polymorphisms in candidate genes: Implications for the current treatment of Parkinson's disease. Expert Opin Pharmacother 2006;7:849-55
88. Makoff AJ, Graham JM, Arranz MJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 2000;10:43-8 (Pubitemid 30142812)
89. Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: Case-control study. Arch Neurol 2001;58:209-13 (Pubitemid 32163157)
90. Wang J, Zhao C, Chen B, et al. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease. Neurosci Lett 2004;355:193-6 (Pubitemid 38368736)
91. Kaiser R, Hofer A, Grapengiesser A, et al. L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003;60:1750-5 (Pubitemid 36737068)
92. Goldman JG, Goetz CG, Berry-Kravis E, et al. Genetic polymorphisms of the dopamine transporter gene and hallucinations in Parkinson's disease. Mov Disord 2004;19:S356
93. Ogilvie AD, Battersby S, Bubb VJ, et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 1996;347:731-3 (Pubitemid 26085649)
94. Goldman JG, Goetz CG, Berry-Kravis E, et al. Serotonin transporter gene polymorphisms and hallucinations in Parkinson's disease. Ann Neurol 2004;2004:S8
95. Kiferle L, Ceravolo R, Petrozzi L, et al. Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett 2007;422:228-31 (Pubitemid 47077605)
96. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1556-71 (Pubitemid 47625703)
97. Fox SH, Visanji NP, Johnston TH, et al. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 2006;63:1343-4 (Pubitemid 44379848)
98. Visanji NP, Gomez-Ramirez J, Johnston TH, et al. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006;21:1879-91 (Pubitemid 44848934)
99. Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord 2008;23:484-500 Recent review of scales used to assess PD psychosis.
100. Goetz CG. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S38-41